Single agent Tusp is a fastest and least expensive way to bring Tusp to the market. It is a big hurdle, but in the end it would help a lot for future approvals in combinations. One example is manufacturing. Everybody, including big pharma knows that. Don't underestimate it. Single agent approval would be a huge win for Aptose, good for SP and will increase chances for buyout. You are a big fan of Rice, but he cannot deliver. What he is good at is switching your focus after each failure or misstep.
News 
Market Data 
Discover 
